Search for: "Sabatelli"
Results 21 - 40
of 45
Sorted by Relevance
|
Sort by Date
19 Jan 2016, 8:31 pm
Sabatelli** -- Early last month, the Jackson Laboratory for Genomic Medicine in Farmington, CT held its second annual symposium, "Microbiome Meets Cancer and Immunology. [read post]
3 Mar 2019, 9:28 pm
Sabatelli** -- Lowering carbon dioxide (CO2) levels in our atmosphere is one of the most important challenges to be overcome in the next century. [read post]
3 May 2018, 9:29 pm
Sabatelli** -- The cosmeceutical industry is ever more competitive and continues to grow with a myriad of new cosmeceutical products entering the market every day. [read post]
12 Aug 2018, 8:54 pm
Sabatelli** -- Over the last decade, antibody-drug conjugates (ADCs) have emerged as a highly promising new class of biopharmaceuticals. [read post]
26 Sep 2017, 9:35 pm
Sabatelli** -- As we have discussed in previous installments of "The Emergent Microbiome," we have seen a distinct growth in the interest of the microbial communities found in our environment beyond the confines of the human body. [read post]
13 Dec 2018, 9:36 pm
By Brittany Knight* and Anthony Sabatelli** -- Software is a generic term to refer to a collection of data or executing code used by a computer to implement arithmetic operations or logical operations. [read post]
3 Oct 2018, 9:55 pm
Sabatelli** -- Typically, we think of patents as the main tool that allows for product exclusivity in the pharmaceutical industry. [read post]
11 Aug 2015, 9:59 pm
Sabatelli** -- Microbiome-related therapies typically involve compositions containing bacteria -- often called probiotics -- that treat disease or promote health. [read post]
19 Jul 2018, 8:28 pm
Sabatelli**, and Jonathan Schuchardt*** -- Buried amidst the flurry of recent Federal Circuit subject matter eligibility decisions is a question that could significantly change how Section 101 is applied in patent litigation. [read post]
7 Oct 2014, 9:59 pm
Sabatelli* -- The pharmaceutical industry is an important segment of the world economy. [read post]
5 Oct 2016, 9:59 pm
Sabatelli** -- Many research efforts into the microbiome have focused primarily on the human microbiome, i.e., microorganisms within and on the body, and how changes in these microbial communities correlate with changes in health and disease. [read post]
3 Mar 2015, 9:59 pm
Sabatelli** -- Late last year, the Tufts Center for the Study of Drug Development (CSDD) released a number that would cause jaws to drop all around the healthcare world. [read post]
13 Oct 2015, 9:59 pm
Sabatelli** -- Research into the microbiome focuses heavily on bacteria living in the gut, which houses more bacteria than any other organ. [read post]
19 Dec 2016, 9:41 pm
Sabatelli** -- A contentious patent battle has continued to rage between the Broad Institute at Harvard/MIT and the University of California ("UC"). [read post]
12 Jan 2015, 9:59 pm
Sabatelli** -- If innovation drives progress, then 2014 was the year of progress! [read post]
23 Nov 2016, 8:45 pm
Sabatelli** -- On November 2, 2016, the United States Patent and Trademark Office (USPTO) issued an important and forward-looking memo on Recent Subject Matter Eligibility Decisions for patent applications that offered guidance for drafting claims that may have previously been rendered ineligible under the two-step Alice test for determining patent eligibility (see "USPTO Issues Memorandum on Recent Subject Matter Eligibility Decisions"). [read post]
20 Feb 2017, 9:06 pm
Sabatelli** -- Research into the human microbiome has resulted in such unprecedented amounts of data that challenges related to both interpretation and management have emerged. [read post]
6 Dec 2016, 9:59 pm
Sabatelli** -- Given that the majority of the human microbiome is found in the gut, it is not surprising that most microbiome-based therapeutic approaches have been used to treat gastrointestinal disorders, such as inflammatory bowel disease (IBD) and Clostridium difficile infections. [read post]
17 Mar 2019, 9:59 pm
Sabatelli** As reviewed previously, antibody-drug conjugates (ADCs) are a highly promising class of antitumor drugs that represent a growing proportion of cancer treatments in the development pipeline (see "Antibody Drug Conjugates: The Patent Landscape for a New Class of Cancer Treatment"). [read post]
9 Jan 2019, 9:59 pm
Sabatelli** -- As discussed in our previous article, antibody-drug conjugates (ADCs) have emerged as a highly promising class of anti-cancer drugs, and significant technical innovations are being made in all three components of the ADC, i.e., the antibody, the drug payload, and the linker joining them. [read post]
